Apixaban: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{Drugbox
{{DrugProjectFormSinglePage
| IUPAC_name        = 1-(4-methoxyphenyl)-7-oxo-6-[4-<BR/>(2-oxopiperidin-1-yl)phenyl]-4,5-<BR/>dihydropyrazolo[5,4-c]pyridine-<BR/>3-carboxamide
|authorTag=
| image            = apixaban.png
 
| CAS_number        = 503612-47-3
 
| ATC_prefix        =  
 
| ATC_suffix        =  
<!--Overview-->
| PubChem          = 10182969
 
| DrugBank          =  
|genericName=
| C=25 | H=25 | N=5 | O=4
 
| molecular_weight  = 459.497
 
| bioavailability  =  
 
| protein_bound    =  
|aOrAn=
| metabolism        =  
 
| elimination_half-life =  
a
| excretion        =  
 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
|drugClass=
| pregnancy_US      = <!-- A / B            / C / D / X -->
 
| pregnancy_category=
 
| legal_AU          = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
 
| legal_CA          = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
|indication=
| legal_UK          = <!-- GSL        / P      / POM / CD / Class A, B, C -->
 
| legal_US          = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
 
| legal_status      =  
 
| routes_of_administration = oral
|hasBlackBoxWarning=
}}
 
Yes
 
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Condition1
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
 
 
<!--Mechanism of Action-->
 
|mechAction=
 
*
 
<!--Structure-->
 
|structure=
 
*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=


{{SI}}
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


{{CMG}}
<!--How Supplied-->


|howSupplied=


*


==Overview==
<!--Patient Counseling Information-->
'''Apixaban''' (manufacturer's designation BMS-562247-01) is a compound being investigated as an [[anticoagulant]]. It acts by inhibiting coagulation [[factor X]]a. It is presently undergoing phase III trials in the prevention of [[venous thromboembolism]], together with a number of related competing compounds, such as [[rivaroxaban]].<ref>{{cite journal |author=Turpie AG |title=Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases |journal=Arterioscler. Thromb. Vasc. Biol. |volume=27 |issue=6 |pages=1238-47 |year=2007 |pmid=17379841 |doi=10.1161/ATVBAHA.107.139402}}</ref> It is being marketed in a joint venture by Pfizer and Bristol-Myers-Squibb.<ref>{{cite web |url=http://newsroom.bms.com/index.php?s=press_releases&item=254 |title=Bristol-Myers Squibb News Release 26 April 2007 |accessdate=2007-09-15 |format= |work=}}</ref>


==Acute Coronary Syndrome (ACS) Studies==
|fdaPatientInfo=
===APPRAISE-1 Trial===
Results of the Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome (APPRAISE-1) demonstrate that administration of the factor Xa inhibitor [[Apixaban]] on top of current [[antiplatelet therapy]] for 6 months post-acute coronary syndrome (ACS) leads to increased bleeding in a dose-dependent fashion and reduced [[ischemic]] events. The data were presented by Dr. John H. Alexander and Dr. Lars Wallentin at the European Society of Cardiology Congress 2008 Hot Line III session. 


The goal of this trial was 1) to evaluate the effect on [[bleeding]] of 4 doses of Apixaban vs. [[placebo]] given over 26 weeks in patients with a recent [[ACS]] receiving current evidence based care ([[Aspirin]] ≤165 mg/d, [[Clopidogrel]] per MD discretion) and 2) to determine the optimal dose of Apixaban for further investigation. Major bleeding was defined as bleeding with a fall in [[hemoglobin]] of ≥2 g/dl, or bleeding with [[transfusion]] of ≥2 units of PRBC or whole [[blood]], or bleeding that occurs in a critical location (i.e. [[brain]] or [[spine]]), or bleeding that causes death.
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


The APPRAISE-1 trial was a [[clinical trial|phase 2]], [[randomized]], double-blind, placebo-controlled, parallel arm study that enrolled 1,715 patients from Europe (n=1,305) and North America (n=410). Phase A of the study randomized 547 patients to 10 mg Apixaban daily (Apixaban 10 mg QD, n=184), 2.5 mg Apixaban twice daily (Apixaban 2.5 mg BID, n=179), and placebo (n=184). In phase B, 1168 patients were randomized to Apixaban 10 mg QD (n=134), Apixaban 2.5 mg BID (n=138), placebo (n=427), Apixaban 10 mg BID (n=248), and Apixaban 20 mg QD (n=221). All patients received the study drug for 6 months. The latter two groups (10 mg BID and 20 mg QD, n=469) were discontinued prematurely from the study due to excess bleeding.
<!--Precautions with Alcohol-->


The inclusion criteria selected patients age 18-90 years with recent [[ACS]] (≤7 days) and at least one additional risk factor such as age ≥65 years, [[diabetes mellitus]], or prior [[MI]] within the past 12 months. The primary safety endpoint was International Society of Thrombosis and Haemostasis (ISTH) major or clinically relevant non-major (CRNM) bleeding. The secondary efficacy endpoint included cardiovascular (CV) death, [[MI]], severe recurrent [[ischemia]], or [[ischemic stroke]]. The duration of follow-up was a mean of 6 months.
|alcohol=


Compared to [[placebo]], [[Apixaban]] treatment was associated with increased [[bleeding]] among patients with a recent [[ACS]] according to the ISTH major or CRNM and Thrombolysis in Myocardial Infarction (TIMI) [[bleeding]] definitions. According to the ISTH major or CRNM definition, [[bleeding]] occurred in 7.9% of patients receiving [[Apixaban]] 10 mg QD (n=315), 5.7% in the [[Apixaban]] 2.5 mg BID arm (n=315) and 3.0% in the [[placebo]] group (n=599). HR: 2.45, 95% CI: 1.31 to 4.61, p = 0.005 for [[Apixaban]] 10 mg QD vs. [[placebo]] and HR: 1.78, 95% CI: 0.91 to 3.48, p = 0.09 for [[Apixaban]] 2.5 mg BID vs. [[placebo]]. 1.0%, 0.0%, 0.3% of patients being administered [[Apixaban]] 10 mg QD (n=315), [[Apixaban]] 2.5 mg BID (n=315) and [[placebo]] (n=599), respectively, experienced major [[bleeding]] by the TIMI definition.  
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


When [[bleeding]] was stratified by [[Clopidogrel]] status, the study drug was still associated with increased [[bleeding]]. Patients taking [[Clopidogrel]]: 9.1% [[bleeding]] for [[Apixaban]] 10 mg QD (n=241), 7.0% for [[Apixaban]] 2.5 mg BID (n=230), 3.1% for [[placebo]] (n=453); No [[Clopidogrel]]: 4.1%, 2.4%, 2.7% [[bleeding]] for [[Apixaban]] 10 mg QD (n=74), [[Apixaban]] 2.5 mg BID (n=85) and [[placebo]] (n=146) respectively.
<!--Brand Names-->


The secondary endpoints of CV death, [[MI]], severe recurrent [[ischemia]], or [[ischemic stroke]] were most prevalent in the [[placebo]] group (6.0%, 7.6%, and 8.7% in the [[Apixaban]] 10 mg QD n=318, [[Apixaban]] 2.5 mg BID n=317 and [[placebo]] groups n=611, respectively, HR 0.61, 95% CI 0.35 to 1.04, p = 0.07 for [[Apixaban]] 10 mg QD vs. [[placebo]] and HR 0.73, 95% CI 0.44 to 1.19, p = 0.21 for [[Apixaban]] 2.5 mg BID vs. [[placebo]]) while CV death alone occurred most frequently in the [[Apixaban]] 2.5 mg BID group (1.3% [[Apixaban]] 10 mg QD n = 318, 3.5% [[Apixaban]] 2.5 mg BID n = 317, 1.8% [[placebo]] n = 611).
|brandNames=


When secondary endpoints were stratified by [[Clopidogrel]] status, [[placebo]] was associated with the most [[ischemic]] events. Patients taking [[Clopidogrel]]: 4.9% for [[Apixaban]] 10 mg QD (n=243), 5.6% for [[Apixaban]] 2.5 mg BID (n=232), 6.5 % for [[placebo]] (n=462); No [[Clopidogrel]]: 9.3%, 12.9%, 15.4% for [[Apixaban]] 10 mg QD (n=75), [[Apixaban]] 2.5 mg BID (n=85) and [[placebo]] (n=149) respectively.
* ®<ref>{{Cite web | title = | url = }}</ref>


APPRAISE-1 represents the first trial to combine [[anticoagulation]] with a direct factor Xa inhibitor in the treatment of patients with a recent [[ACS]] already receiving [[antiplatelet therapy]]. Overall, the results suggest that administration of [[Apixaban]] on top of current [[antiplatelet therapy]] for 6 months post-[[ACS]] leads to increased [[bleeding]] in a dose-dependent fashion and reduced [[ischemic]] events. Similar outcomes were found among patients taking [[Aspirin]] or [[Aspirin]] + [[Clopidogrel]].
<!--Look-Alike Drug Names-->


APPRAISE-1 was supported by Bristol-Myers Squibb.
|lookAlike=


[http://clintrialresults.org/Slides/APPRAISE%20ESC08.ppt View the slides here]
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>


References
<!--Drug Shortage Status-->
# John H. Alexander, Lars Wallentin, APPRAISE-1 Committees and Investigators. Safety of the factor Xa inhibitor, Apixaban, in combination with antiplatelet therapy after acute coronary syndromes: Results from the APPRAISE-1 dose guiding trial. As presented at ESC 2008.


==Venous Thromboembolism (VTE) Studies==
|drugShortage=
}}


A 2007 trial showed that apixaban was equivalent to enoxaparin/open-label heparin in preventing thrombosis is patients who had undergone a knee replacement.<ref>{{cite journal |author=Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D |title=The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement |journal=J. Thromb. Haemost. |volume=5 |issue=12 |pages=2368–75 |year=2007 |pmid=17868430 |doi=10.1111/j.1538-7836.2007.02764.x}}</ref>
<!--Pill Image-->


===Pill Images===
{{TempDrugImages}}
{{TempDrugImages}}
{{PillImage|fileName=ELIQUIS_NDC_00030894.jpg|drugName=ELIQUIS|NDC=00030894|drugAuthor=E.R. Squibb & Sons, L.L.C.|ingredients=apixaban[apixaban]|pillImprint=894;5|dosageValue=5|dosageUnit=mg|pillColor=Pink|pillShape=Oval|pillSize=10|pillScore=1}}
{{PillImage|fileName=ELIQUIS_NDC_00030894.jpg|drugName=ELIQUIS|NDC=00030894|drugAuthor=E.R. Squibb & Sons, L.L.C.|ingredients=apixaban[apixaban]|pillImprint=894;5|dosageValue=5|dosageUnit=mg|pillColor=Pink|pillShape=Oval|pillSize=10|pillScore=1}}


<!--Label Display Image-->


==References==
{{LabelImage
<references/>
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


<!--Category-->
[[Category:Drug]]
[[Category:Cardiovascular Drugs]]
[[Category:Anticoagulants]]
[[Category:Anticoagulants]]
[[Category:Pyrazoles]]
[[de:Apixaban]]
{{WH}}
{{WS}}

Revision as of 19:39, 27 July 2014

Apixaban
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Apixaban is a that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Apixaban in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Apixaban in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Apixaban in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Apixaban in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Apixaban in pediatric patients.

Contraindications

  • Condition1

Warnings

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Apixaban in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Apixaban in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Apixaban in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Apixaban during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Apixaban with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Apixaban with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Apixaban with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Apixaban with respect to specific gender populations.

Race

There is no FDA guidance on the use of Apixaban with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Apixaban in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Apixaban in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Apixaban in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Apixaban in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Apixaban in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Apixaban in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Apixaban in the drug label.

Pharmacology

There is limited information regarding Apixaban Pharmacology in the drug label.

Mechanism of Action

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Apixaban in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Apixaban in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Apixaban in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Apixaban in the drug label.

How Supplied

Storage

There is limited information regarding Apixaban Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Apixaban |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Apixaban |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Apixaban in the drug label.

Precautions with Alcohol

  • Alcohol-Apixaban interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)


{{#ask: Page Name::Apixaban |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject: 

 |Page Name=Apixaban
 |Pill Name=ELIQUIS_NDC_00030894.jpg
 |Drug Name=ELIQUIS
 |Pill Ingred=apixaban[apixaban]|+sep=;
 |Pill Imprint=894;5
 |Pill Dosage=5 mg
 |Pill Color=Pink|+sep=;
 |Pill Shape=Oval
 |Pill Size (mm)=10
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=E.R. Squibb & Sons, L.L.C.
 |NDC=00030894

}}


{{#subobject: 

 |Label Page=Apixaban
 |Label Name=Apixaban11.png

}}


{{#subobject: 

 |Label Page=Apixaban
 |Label Name=Apixaban11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Apixaban&oldid=1002848"